Shuk-Mei Ho
Concepts (499)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Phenols | 29 | 2021 | 120 | 8.190 |
Why?
| Benzhydryl Compounds | 28 | 2021 | 75 | 7.260 |
Why?
| Prostatic Neoplasms | 32 | 2022 | 415 | 5.770 |
Why?
| Prostate | 22 | 2020 | 117 | 4.340 |
Why?
| DNA Methylation | 23 | 2020 | 574 | 4.140 |
Why?
| Estradiol | 19 | 2021 | 219 | 4.140 |
Why?
| Epigenesis, Genetic | 18 | 2021 | 399 | 4.080 |
Why?
| Endocrine Disruptors | 14 | 2021 | 27 | 3.360 |
Why?
| Estrogen Receptor beta | 17 | 2019 | 56 | 3.340 |
Why?
| Prenatal Exposure Delayed Effects | 11 | 2021 | 173 | 3.010 |
Why?
| Gene Expression Regulation, Neoplastic | 13 | 2017 | 866 | 2.190 |
Why?
| Estrogens | 12 | 2020 | 244 | 1.840 |
Why?
| Testosterone | 8 | 2016 | 119 | 1.790 |
Why?
| Maternal Exposure | 4 | 2021 | 87 | 1.770 |
Why?
| Air Pollutants, Occupational | 4 | 2020 | 18 | 1.670 |
Why?
| Environmental Pollutants | 6 | 2018 | 101 | 1.650 |
Why?
| Occupational Exposure | 4 | 2021 | 129 | 1.590 |
Why?
| Spermatogenesis | 2 | 2021 | 9 | 1.410 |
Why?
| Environmental Exposure | 7 | 2018 | 205 | 1.330 |
Why?
| Diet, High-Fat | 4 | 2021 | 216 | 1.270 |
Why?
| Rats | 24 | 2021 | 3415 | 1.240 |
Why?
| Asthma | 4 | 2013 | 293 | 1.180 |
Why?
| Male | 62 | 2022 | 27334 | 1.170 |
Why?
| Animals | 48 | 2022 | 14385 | 1.140 |
Why?
| CpG Islands | 7 | 2016 | 104 | 1.110 |
Why?
| Receptors, Estrogen | 6 | 2019 | 131 | 1.100 |
Why?
| Centrosome | 2 | 2016 | 11 | 1.080 |
Why?
| Pregnancy | 19 | 2023 | 2620 | 1.070 |
Why?
| Mammary Neoplasms, Experimental | 2 | 2017 | 135 | 1.060 |
Why?
| Breast Neoplasms | 8 | 2016 | 1248 | 1.050 |
Why?
| Veterans | 2 | 2021 | 629 | 0.980 |
Why?
| Butter | 2 | 2021 | 6 | 0.980 |
Why?
| Cell Line, Tumor | 19 | 2020 | 1550 | 0.940 |
Why?
| Adenocarcinoma | 4 | 2015 | 428 | 0.940 |
Why?
| Metallothionein | 2 | 2015 | 11 | 0.920 |
Why?
| Rats, Sprague-Dawley | 15 | 2021 | 1663 | 0.900 |
Why?
| Cell Movement | 4 | 2014 | 271 | 0.880 |
Why?
| Female | 42 | 2023 | 28441 | 0.880 |
Why?
| Humans | 67 | 2023 | 54284 | 0.860 |
Why?
| Response Elements | 2 | 2013 | 32 | 0.860 |
Why?
| Gene Expression Profiling | 9 | 2015 | 1138 | 0.860 |
Why?
| Estrogens, Non-Steroidal | 8 | 2015 | 14 | 0.830 |
Why?
| Infertility, Male | 1 | 2021 | 14 | 0.830 |
Why?
| Air Pollutants | 3 | 2012 | 70 | 0.820 |
Why?
| Promoter Regions, Genetic | 8 | 2019 | 520 | 0.820 |
Why?
| Dietary Fats | 1 | 2021 | 142 | 0.770 |
Why?
| Toxicity Tests | 1 | 2020 | 52 | 0.760 |
Why?
| Cell Proliferation | 9 | 2017 | 1096 | 0.760 |
Why?
| Sleep Initiation and Maintenance Disorders | 1 | 2020 | 43 | 0.750 |
Why?
| Signal Transduction | 11 | 2020 | 1753 | 0.740 |
Why?
| Racemases and Epimerases | 2 | 2011 | 15 | 0.740 |
Why?
| MicroRNAs | 5 | 2016 | 386 | 0.740 |
Why?
| Disease Susceptibility | 4 | 2012 | 95 | 0.700 |
Why?
| Gene Regulatory Networks | 3 | 2017 | 124 | 0.680 |
Why?
| Anxiety | 1 | 2020 | 279 | 0.660 |
Why?
| Military Personnel | 1 | 2020 | 174 | 0.660 |
Why?
| Aging | 4 | 2017 | 784 | 0.660 |
Why?
| Stress, Psychological | 1 | 2020 | 270 | 0.650 |
Why?
| Chromosomes, Human, X | 1 | 2018 | 21 | 0.650 |
Why?
| Receptors, G-Protein-Coupled | 2 | 2016 | 55 | 0.630 |
Why?
| Prostatic Intraepithelial Neoplasia | 3 | 2015 | 6 | 0.620 |
Why?
| Depressive Disorder | 1 | 2020 | 368 | 0.620 |
Why?
| Embryonic Development | 2 | 2015 | 17 | 0.620 |
Why?
| Pneumonia, Viral | 1 | 2020 | 184 | 0.600 |
Why?
| Genetic Predisposition to Disease | 4 | 2015 | 570 | 0.600 |
Why?
| Cell Transformation, Neoplastic | 5 | 2017 | 200 | 0.590 |
Why?
| Research Design | 2 | 2019 | 374 | 0.590 |
Why?
| Coronavirus Infections | 1 | 2020 | 192 | 0.590 |
Why?
| Rats, Inbred Strains | 5 | 2015 | 172 | 0.580 |
Why?
| Microtubules | 1 | 2016 | 57 | 0.580 |
Why?
| Transcription, Genetic | 4 | 2013 | 418 | 0.570 |
Why?
| Environmental Health | 1 | 2016 | 12 | 0.560 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2016 | 673 | 0.560 |
Why?
| Sexual Maturation | 1 | 2015 | 13 | 0.550 |
Why?
| Endoderm | 1 | 2015 | 1 | 0.550 |
Why?
| Reproduction | 1 | 2016 | 56 | 0.550 |
Why?
| Prostatic Hyperplasia | 3 | 2015 | 44 | 0.550 |
Why?
| Diethylstilbestrol | 2 | 2008 | 12 | 0.550 |
Why?
| Embryo Implantation | 1 | 2015 | 7 | 0.550 |
Why?
| Gene Expression Regulation | 7 | 2018 | 1062 | 0.550 |
Why?
| Transcriptional Activation | 3 | 2013 | 134 | 0.540 |
Why?
| Epigenomics | 1 | 2016 | 67 | 0.540 |
Why?
| Diabetes, Gestational | 1 | 2016 | 54 | 0.540 |
Why?
| DNA | 3 | 2016 | 581 | 0.540 |
Why?
| Vehicle Emissions | 2 | 2012 | 17 | 0.540 |
Why?
| Mesoderm | 1 | 2015 | 33 | 0.540 |
Why?
| RNA, Untranslated | 1 | 2015 | 17 | 0.530 |
Why?
| Histone Code | 1 | 2015 | 32 | 0.530 |
Why?
| Organoids | 1 | 2015 | 41 | 0.530 |
Why?
| Pandemics | 1 | 2020 | 579 | 0.530 |
Why?
| Maternal-Fetal Exchange | 2 | 2020 | 45 | 0.530 |
Why?
| Urinary Bladder Neck Obstruction | 1 | 2015 | 9 | 0.520 |
Why?
| SEER Program | 1 | 2015 | 91 | 0.510 |
Why?
| Forkhead Transcription Factors | 2 | 2012 | 118 | 0.510 |
Why?
| Cyclopentanes | 1 | 2014 | 14 | 0.510 |
Why?
| Quinolines | 1 | 2014 | 40 | 0.500 |
Why?
| Benzo(a)pyrene | 2 | 2012 | 38 | 0.490 |
Why?
| Dose-Response Relationship, Drug | 8 | 2020 | 1476 | 0.490 |
Why?
| Early Detection of Cancer | 1 | 2015 | 162 | 0.470 |
Why?
| Ovarian Neoplasms | 2 | 2010 | 472 | 0.470 |
Why?
| Nerve Tissue Proteins | 2 | 2013 | 199 | 0.470 |
Why?
| Calcium-Binding Proteins | 2 | 2011 | 61 | 0.470 |
Why?
| Histone Acetyltransferases | 1 | 2013 | 22 | 0.460 |
Why?
| Toluene 2,4-Diisocyanate | 1 | 2013 | 1 | 0.460 |
Why?
| Androgens | 4 | 2022 | 68 | 0.460 |
Why?
| Cell Differentiation | 2 | 2015 | 720 | 0.450 |
Why?
| Integrin alpha6 | 1 | 2012 | 2 | 0.450 |
Why?
| Cell Division | 1 | 2014 | 330 | 0.450 |
Why?
| Diet | 2 | 2015 | 598 | 0.450 |
Why?
| Laminin | 1 | 2012 | 29 | 0.450 |
Why?
| Transcriptome | 1 | 2015 | 346 | 0.440 |
Why?
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2012 | 1 | 0.440 |
Why?
| Dual-Specificity Phosphatases | 1 | 2012 | 2 | 0.440 |
Why?
| Firefighters | 1 | 2012 | 7 | 0.430 |
Why?
| Gene-Environment Interaction | 1 | 2012 | 44 | 0.430 |
Why?
| Interferon-gamma | 1 | 2013 | 195 | 0.430 |
Why?
| HMGN Proteins | 1 | 2011 | 1 | 0.420 |
Why?
| Colorectal Neoplasms | 1 | 2015 | 236 | 0.420 |
Why?
| Occupational Diseases | 1 | 2013 | 93 | 0.420 |
Why?
| RNA, Small Interfering | 5 | 2016 | 252 | 0.410 |
Why?
| Mass Screening | 1 | 2015 | 370 | 0.410 |
Why?
| Receptors, Androgen | 3 | 2022 | 49 | 0.410 |
Why?
| Oxidative Stress | 3 | 2007 | 958 | 0.400 |
Why?
| Endocrine Glands | 1 | 2011 | 5 | 0.400 |
Why?
| Endocrine System Diseases | 1 | 2011 | 9 | 0.400 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 543 | 0.400 |
Why?
| Inhibitor of Apoptosis Proteins | 1 | 2010 | 21 | 0.390 |
Why?
| Risk | 4 | 2017 | 343 | 0.390 |
Why?
| Prolactin | 1 | 2010 | 43 | 0.380 |
Why?
| RNA | 2 | 2012 | 202 | 0.380 |
Why?
| Introns | 1 | 2010 | 49 | 0.370 |
Why?
| Genetic Vectors | 1 | 2010 | 139 | 0.370 |
Why?
| Membrane Proteins | 2 | 2010 | 389 | 0.360 |
Why?
| Gene Silencing | 1 | 2010 | 129 | 0.360 |
Why?
| Immunohistochemistry | 7 | 2016 | 1089 | 0.350 |
Why?
| Coenzyme A Ligases | 1 | 2009 | 4 | 0.350 |
Why?
| Proteins | 3 | 2008 | 376 | 0.350 |
Why?
| Anticarcinogenic Agents | 2 | 2006 | 35 | 0.350 |
Why?
| RNA, Messenger | 6 | 2022 | 1202 | 0.340 |
Why?
| Histones | 5 | 2016 | 335 | 0.340 |
Why?
| Orphan Nuclear Receptors | 2 | 2019 | 15 | 0.330 |
Why?
| Risk Factors | 5 | 2020 | 3935 | 0.320 |
Why?
| Antigens, Neoplasm | 1 | 2009 | 170 | 0.320 |
Why?
| Deoxyguanosine | 2 | 2007 | 32 | 0.320 |
Why?
| Organ Culture Techniques | 1 | 2007 | 53 | 0.310 |
Why?
| Ethinyl Estradiol | 2 | 2018 | 8 | 0.310 |
Why?
| Polymerase Chain Reaction | 1 | 2009 | 531 | 0.310 |
Why?
| Fetus | 1 | 2009 | 227 | 0.300 |
Why?
| Apigenin | 1 | 2006 | 5 | 0.300 |
Why?
| Estrogen Receptor Modulators | 1 | 2006 | 6 | 0.300 |
Why?
| Age Factors | 4 | 2015 | 1198 | 0.300 |
Why?
| Molecular Biology | 1 | 2007 | 31 | 0.290 |
Why?
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2006 | 7 | 0.290 |
Why?
| Adult | 10 | 2020 | 14207 | 0.290 |
Why?
| Protein Isoforms | 4 | 2013 | 124 | 0.290 |
Why?
| Epithelium | 3 | 2014 | 68 | 0.280 |
Why?
| Sex Characteristics | 2 | 2018 | 214 | 0.280 |
Why?
| Disease Models, Animal | 5 | 2021 | 1639 | 0.280 |
Why?
| Mice | 11 | 2022 | 6413 | 0.280 |
Why?
| Cells, Cultured | 6 | 2019 | 1737 | 0.270 |
Why?
| Epithelial Cells | 3 | 2015 | 255 | 0.270 |
Why?
| Proteomics | 1 | 2008 | 343 | 0.260 |
Why?
| Cytochrome P-450 CYP1A1 | 1 | 2005 | 46 | 0.260 |
Why?
| Carcinogens | 3 | 2015 | 231 | 0.250 |
Why?
| Molecular Sequence Data | 4 | 2009 | 980 | 0.250 |
Why?
| Animals, Newborn | 5 | 2018 | 396 | 0.250 |
Why?
| NF-kappa B | 1 | 2006 | 335 | 0.240 |
Why?
| Estrogen Receptor alpha | 3 | 2019 | 95 | 0.240 |
Why?
| DNA-Binding Proteins | 3 | 2016 | 462 | 0.240 |
Why?
| Middle Aged | 9 | 2020 | 13088 | 0.230 |
Why?
| Antioxidants | 1 | 2006 | 297 | 0.230 |
Why?
| Stem Cells | 2 | 2015 | 193 | 0.230 |
Why?
| Tumor Suppressor Proteins | 2 | 2020 | 141 | 0.220 |
Why?
| Estrogen Antagonists | 1 | 2002 | 19 | 0.220 |
Why?
| Immediate-Early Proteins | 1 | 2002 | 19 | 0.220 |
Why?
| Cell Line | 3 | 2016 | 1153 | 0.220 |
Why?
| Kidney | 1 | 2007 | 820 | 0.210 |
Why?
| Reproducibility of Results | 5 | 2020 | 1304 | 0.210 |
Why?
| Arabidopsis Proteins | 1 | 2002 | 31 | 0.210 |
Why?
| Base Sequence | 3 | 2011 | 719 | 0.210 |
Why?
| Inheritance Patterns | 1 | 2021 | 27 | 0.210 |
Why?
| Incineration | 1 | 2021 | 6 | 0.200 |
Why?
| Testis | 1 | 2021 | 65 | 0.200 |
Why?
| Gene Expression | 3 | 2011 | 664 | 0.200 |
Why?
| Maternal Nutritional Physiological Phenomena | 1 | 2021 | 51 | 0.200 |
Why?
| HEK293 Cells | 4 | 2016 | 245 | 0.200 |
Why?
| Loneliness | 1 | 2020 | 13 | 0.190 |
Why?
| Hypesthesia | 1 | 2020 | 18 | 0.190 |
Why?
| Mammary Glands, Animal | 2 | 2020 | 69 | 0.190 |
Why?
| Antineoplastic Agents, Hormonal | 2 | 2014 | 49 | 0.190 |
Why?
| DNA Modification Methylases | 1 | 2020 | 32 | 0.190 |
Why?
| Isocitrate Dehydrogenase | 1 | 2020 | 21 | 0.190 |
Why?
| Memory Disorders | 1 | 2020 | 62 | 0.190 |
Why?
| Pyruvate Kinase | 1 | 2020 | 8 | 0.190 |
Why?
| DNA Repair Enzymes | 1 | 2020 | 50 | 0.180 |
Why?
| Fear | 1 | 2020 | 87 | 0.180 |
Why?
| Phenotype | 2 | 2015 | 820 | 0.180 |
Why?
| Sequence Analysis, RNA | 1 | 2020 | 107 | 0.180 |
Why?
| Real-Time Polymerase Chain Reaction | 3 | 2014 | 206 | 0.180 |
Why?
| Random Allocation | 2 | 2017 | 312 | 0.180 |
Why?
| Methylation | 2 | 2020 | 130 | 0.180 |
Why?
| Neoplasm Metastasis | 2 | 2014 | 252 | 0.180 |
Why?
| Glioma | 1 | 2020 | 78 | 0.180 |
Why?
| Image Processing, Computer-Assisted | 2 | 2016 | 256 | 0.180 |
Why?
| Endometrial Neoplasms | 1 | 2020 | 144 | 0.180 |
Why?
| Urethra | 2 | 2020 | 80 | 0.170 |
Why?
| Collagen Type III | 1 | 2019 | 10 | 0.170 |
Why?
| Subcellular Fractions | 2 | 2012 | 43 | 0.170 |
Why?
| Gonadal Steroid Hormones | 2 | 2011 | 42 | 0.170 |
Why?
| Blotting, Western | 3 | 2016 | 683 | 0.170 |
Why?
| Mice, Transgenic | 2 | 2015 | 656 | 0.170 |
Why?
| Adaptation, Psychological | 1 | 2020 | 244 | 0.170 |
Why?
| Liver Failure, Acute | 1 | 2019 | 64 | 0.170 |
Why?
| Tissue Array Analysis | 3 | 2016 | 50 | 0.170 |
Why?
| Models, Genetic | 2 | 2011 | 209 | 0.160 |
Why?
| Denmark | 1 | 2018 | 42 | 0.160 |
Why?
| Methylmercury Compounds | 1 | 2018 | 13 | 0.160 |
Why?
| Collagen Type I | 1 | 2019 | 97 | 0.160 |
Why?
| Polychlorinated Biphenyls | 1 | 2018 | 26 | 0.160 |
Why?
| DNA Primers | 2 | 2011 | 225 | 0.160 |
Why?
| Chromatin Immunoprecipitation | 2 | 2016 | 55 | 0.160 |
Why?
| Linear Models | 1 | 2019 | 309 | 0.160 |
Why?
| Electronic Waste | 1 | 2017 | 1 | 0.160 |
Why?
| Hair | 1 | 2018 | 53 | 0.160 |
Why?
| Fetal Blood | 1 | 2018 | 67 | 0.160 |
Why?
| Cohort Studies | 2 | 2014 | 1543 | 0.160 |
Why?
| Computational Biology | 2 | 2017 | 231 | 0.160 |
Why?
| Cadmium | 1 | 2017 | 27 | 0.160 |
Why?
| Lysine | 2 | 2015 | 102 | 0.160 |
Why?
| Histone Demethylases | 1 | 2017 | 15 | 0.160 |
Why?
| Receptors, Aryl Hydrocarbon | 1 | 2017 | 29 | 0.160 |
Why?
| Urethane | 1 | 2017 | 8 | 0.160 |
Why?
| Water Pollutants, Chemical | 1 | 2018 | 55 | 0.150 |
Why?
| Genomic Imprinting | 2 | 2008 | 11 | 0.150 |
Why?
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 2 | 2008 | 10 | 0.150 |
Why?
| Neoplasm Staging | 2 | 2014 | 806 | 0.150 |
Why?
| Survival Analysis | 2 | 2016 | 735 | 0.150 |
Why?
| Infant, Newborn | 3 | 2023 | 2907 | 0.150 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2019 | 250 | 0.150 |
Why?
| Tumor Cells, Cultured | 2 | 2014 | 477 | 0.150 |
Why?
| Acetylation | 2 | 2015 | 99 | 0.150 |
Why?
| Cholesterol | 1 | 2017 | 155 | 0.150 |
Why?
| Protein Binding | 2 | 2011 | 736 | 0.150 |
Why?
| 5-Methylcytosine | 1 | 2016 | 18 | 0.140 |
Why?
| Brain Neoplasms | 1 | 2020 | 284 | 0.140 |
Why?
| Fibroblasts | 1 | 2019 | 386 | 0.140 |
Why?
| Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 16 | 0.140 |
Why?
| Methyltransferases | 1 | 2016 | 28 | 0.140 |
Why?
| Hippocampus | 1 | 2018 | 242 | 0.140 |
Why?
| Genetic Loci | 1 | 2016 | 58 | 0.140 |
Why?
| Histone-Lysine N-Methyltransferase | 1 | 2016 | 58 | 0.140 |
Why?
| Hepatocyte Nuclear Factor 4 | 1 | 2015 | 3 | 0.140 |
Why?
| Genital Neoplasms, Male | 1 | 2015 | 3 | 0.140 |
Why?
| Heart Diseases | 1 | 2019 | 237 | 0.140 |
Why?
| Pregnancy Outcome | 1 | 2017 | 249 | 0.140 |
Why?
| Exercise | 1 | 2020 | 552 | 0.140 |
Why?
| Myocardium | 1 | 2019 | 441 | 0.140 |
Why?
| Exosomes | 1 | 2016 | 45 | 0.140 |
Why?
| Immunologic Surveillance | 1 | 2015 | 14 | 0.140 |
Why?
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2015 | 54 | 0.140 |
Why?
| Myeloid Cells | 1 | 2015 | 37 | 0.130 |
Why?
| Interferons | 1 | 2015 | 44 | 0.130 |
Why?
| Prognosis | 3 | 2017 | 2118 | 0.130 |
Why?
| Prostatectomy | 1 | 2016 | 87 | 0.130 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2016 | 119 | 0.130 |
Why?
| Incidence | 2 | 2017 | 1082 | 0.130 |
Why?
| Environment | 1 | 2016 | 103 | 0.130 |
Why?
| Genital Neoplasms, Female | 1 | 2015 | 38 | 0.130 |
Why?
| Mammaglobin B | 1 | 2015 | 1 | 0.130 |
Why?
| Isoenzymes | 2 | 2006 | 177 | 0.130 |
Why?
| Urinary Bladder | 1 | 2015 | 83 | 0.130 |
Why?
| Placenta | 1 | 2016 | 135 | 0.130 |
Why?
| Inflammasomes | 1 | 2015 | 60 | 0.130 |
Why?
| Cluster Analysis | 1 | 2015 | 249 | 0.130 |
Why?
| Hyperplasia | 1 | 2015 | 107 | 0.130 |
Why?
| Age Distribution | 1 | 2015 | 198 | 0.130 |
Why?
| Lung Neoplasms | 2 | 2020 | 642 | 0.130 |
Why?
| Aged | 6 | 2020 | 10054 | 0.130 |
Why?
| Models, Biological | 3 | 2017 | 823 | 0.130 |
Why?
| Precancerous Conditions | 2 | 2006 | 93 | 0.130 |
Why?
| Schools | 1 | 2016 | 176 | 0.130 |
Why?
| Polycomb Repressive Complex 2 | 1 | 2014 | 50 | 0.130 |
Why?
| Gestational Age | 1 | 2016 | 435 | 0.120 |
Why?
| Immunoenzyme Techniques | 1 | 2014 | 165 | 0.120 |
Why?
| Up-Regulation | 4 | 2019 | 508 | 0.120 |
Why?
| Fluorescent Antibody Technique, Indirect | 1 | 2014 | 26 | 0.120 |
Why?
| Receptors, N-Methyl-D-Aspartate | 1 | 2015 | 121 | 0.120 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2014 | 219 | 0.120 |
Why?
| Protein Processing, Post-Translational | 2 | 2012 | 183 | 0.120 |
Why?
| Age of Onset | 1 | 2014 | 117 | 0.120 |
Why?
| Kaplan-Meier Estimate | 2 | 2017 | 514 | 0.120 |
Why?
| Gene Deletion | 1 | 2015 | 293 | 0.120 |
Why?
| Neoplasm Proteins | 1 | 2016 | 359 | 0.120 |
Why?
| Methacholine Chloride | 1 | 2013 | 4 | 0.120 |
Why?
| Liver Neoplasms | 1 | 2017 | 352 | 0.110 |
Why?
| Oligonucleotide Array Sequence Analysis | 3 | 2007 | 474 | 0.110 |
Why?
| Repressor Proteins | 1 | 2014 | 165 | 0.110 |
Why?
| Exons | 1 | 2013 | 105 | 0.110 |
Why?
| MAP Kinase Kinase Kinase 1 | 1 | 2012 | 4 | 0.110 |
Why?
| Saliva | 1 | 2012 | 63 | 0.110 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2012 | 83 | 0.110 |
Why?
| Ovary | 2 | 2020 | 105 | 0.110 |
Why?
| Eyelids | 1 | 2012 | 33 | 0.110 |
Why?
| Smoke | 1 | 2012 | 20 | 0.110 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 158 | 0.110 |
Why?
| Cell Adhesion | 1 | 2012 | 171 | 0.110 |
Why?
| Young Adult | 4 | 2020 | 4318 | 0.110 |
Why?
| Child, Preschool | 2 | 2012 | 4147 | 0.100 |
Why?
| RNA Splicing | 1 | 2012 | 38 | 0.100 |
Why?
| Azacitidine | 1 | 2011 | 37 | 0.100 |
Why?
| Phytoestrogens | 2 | 2014 | 20 | 0.100 |
Why?
| Flow Cytometry | 2 | 2014 | 546 | 0.100 |
Why?
| Phosphorylation | 3 | 2020 | 614 | 0.100 |
Why?
| Carrier Proteins | 1 | 2013 | 359 | 0.100 |
Why?
| Adult Stem Cells | 1 | 2011 | 10 | 0.100 |
Why?
| Peptide Hormones | 1 | 2011 | 4 | 0.100 |
Why?
| Thyroid Hormones | 1 | 2011 | 18 | 0.100 |
Why?
| Kruppel-Like Transcription Factors | 1 | 2011 | 40 | 0.100 |
Why?
| Calcitriol | 1 | 2011 | 40 | 0.100 |
Why?
| Chemokine CXCL13 | 1 | 2010 | 4 | 0.100 |
Why?
| Bromocriptine | 1 | 2010 | 5 | 0.100 |
Why?
| Calgranulin B | 1 | 2010 | 6 | 0.100 |
Why?
| Muscle Proteins | 1 | 2013 | 307 | 0.100 |
Why?
| Cell Nucleus | 2 | 2016 | 203 | 0.100 |
Why?
| Tretinoin | 1 | 2011 | 56 | 0.100 |
Why?
| Sensitivity and Specificity | 1 | 2013 | 923 | 0.090 |
Why?
| Microscopy, Confocal | 1 | 2010 | 110 | 0.090 |
Why?
| In Situ Hybridization | 1 | 2010 | 82 | 0.090 |
Why?
| Nitric Oxide | 1 | 2012 | 298 | 0.090 |
Why?
| Electrophoretic Mobility Shift Assay | 1 | 2010 | 74 | 0.090 |
Why?
| Staining and Labeling | 2 | 2016 | 106 | 0.090 |
Why?
| Interleukin-1beta | 1 | 2010 | 92 | 0.090 |
Why?
| Microscopy, Fluorescence | 1 | 2010 | 198 | 0.090 |
Why?
| New York City | 1 | 2009 | 24 | 0.090 |
Why?
| Disease-Free Survival | 1 | 2010 | 485 | 0.090 |
Why?
| Binding Sites | 2 | 2022 | 440 | 0.090 |
Why?
| Ecotoxicology | 1 | 2008 | 4 | 0.090 |
Why?
| Proportional Hazards Models | 1 | 2010 | 431 | 0.080 |
Why?
| Administration, Oral | 2 | 2010 | 459 | 0.080 |
Why?
| Follow-Up Studies | 1 | 2014 | 2387 | 0.080 |
Why?
| Clinical Laboratory Techniques | 1 | 2008 | 31 | 0.080 |
Why?
| Mice, Nude | 3 | 2014 | 283 | 0.080 |
Why?
| Public Health Practice | 1 | 2008 | 43 | 0.080 |
Why?
| ROC Curve | 1 | 2009 | 259 | 0.080 |
Why?
| Child | 2 | 2012 | 7341 | 0.080 |
Why?
| Behavior, Animal | 2 | 2020 | 200 | 0.080 |
Why?
| NADH, NADPH Oxidoreductases | 1 | 2007 | 11 | 0.080 |
Why?
| Microdissection | 1 | 2007 | 24 | 0.080 |
Why?
| Cyclooxygenase 2 | 1 | 2007 | 49 | 0.080 |
Why?
| United States | 3 | 2015 | 5217 | 0.080 |
Why?
| Apoptosis | 1 | 2013 | 1300 | 0.080 |
Why?
| Nitric Oxide Synthase | 1 | 2007 | 102 | 0.080 |
Why?
| Lasers | 1 | 2007 | 141 | 0.070 |
Why?
| Presenilin-2 | 1 | 2006 | 3 | 0.070 |
Why?
| Yeasts | 1 | 2006 | 10 | 0.070 |
Why?
| Sequence Analysis, Protein | 1 | 2006 | 21 | 0.070 |
Why?
| Mice, Inbred C57BL | 3 | 2019 | 1999 | 0.070 |
Why?
| Dimerization | 1 | 2006 | 59 | 0.070 |
Why?
| Proteome | 1 | 2008 | 178 | 0.070 |
Why?
| Growth Differentiation Factor 1 | 1 | 2006 | 2 | 0.070 |
Why?
| Consensus | 1 | 2007 | 157 | 0.070 |
Why?
| Caspase 3 | 1 | 2006 | 135 | 0.070 |
Why?
| Protein Biosynthesis | 2 | 2013 | 273 | 0.070 |
Why?
| Retrospective Studies | 2 | 2016 | 6432 | 0.070 |
Why?
| Interleukin-12 | 1 | 2006 | 37 | 0.070 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2006 | 52 | 0.070 |
Why?
| Spinacia oleracea | 1 | 2006 | 8 | 0.070 |
Why?
| Oxidation-Reduction | 1 | 2007 | 382 | 0.070 |
Why?
| Enzyme Activation | 1 | 2006 | 329 | 0.070 |
Why?
| Interleukin-8 | 1 | 2006 | 97 | 0.070 |
Why?
| Phytotherapy | 1 | 2006 | 38 | 0.070 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2006 | 122 | 0.070 |
Why?
| Risk Assessment | 4 | 2015 | 1361 | 0.060 |
Why?
| MCF-7 Cells | 2 | 2016 | 79 | 0.060 |
Why?
| Models, Molecular | 1 | 2006 | 423 | 0.060 |
Why?
| Alternative Splicing | 1 | 2005 | 64 | 0.060 |
Why?
| Amino Acid Sequence | 1 | 2006 | 767 | 0.060 |
Why?
| Oxygen Consumption | 1 | 2006 | 223 | 0.060 |
Why?
| TATA Box | 1 | 2004 | 9 | 0.060 |
Why?
| Dinucleoside Phosphates | 1 | 2004 | 6 | 0.060 |
Why?
| Antineoplastic Agents | 1 | 2013 | 1300 | 0.060 |
Why?
| Cell Survival | 1 | 2006 | 657 | 0.060 |
Why?
| Tandem Mass Spectrometry | 2 | 2017 | 248 | 0.060 |
Why?
| Transfection | 1 | 2005 | 399 | 0.060 |
Why?
| Chromatography, High Pressure Liquid | 2 | 2017 | 377 | 0.060 |
Why?
| Adolescent | 1 | 2016 | 6897 | 0.060 |
Why?
| Orchiectomy | 1 | 2003 | 38 | 0.060 |
Why?
| Infant | 1 | 2012 | 3817 | 0.060 |
Why?
| Oxidoreductases | 1 | 2003 | 62 | 0.060 |
Why?
| Peptide Elongation Factor 1 | 1 | 2003 | 2 | 0.060 |
Why?
| Clusterin | 1 | 2003 | 6 | 0.060 |
Why?
| Glucosephosphate Dehydrogenase | 1 | 2003 | 7 | 0.060 |
Why?
| Amino Acyl-tRNA Synthetases | 1 | 2003 | 6 | 0.060 |
Why?
| Glutathione Reductase | 1 | 2003 | 15 | 0.060 |
Why?
| Plant Extracts | 1 | 2006 | 193 | 0.060 |
Why?
| Aldehydes | 1 | 2003 | 97 | 0.060 |
Why?
| Glutathione Peroxidase | 1 | 2003 | 28 | 0.060 |
Why?
| Regeneration | 1 | 2003 | 72 | 0.060 |
Why?
| Cytoskeleton | 1 | 2003 | 50 | 0.060 |
Why?
| Postoperative Period | 1 | 2003 | 189 | 0.060 |
Why?
| Malondialdehyde | 1 | 2003 | 63 | 0.060 |
Why?
| Catalase | 1 | 2003 | 74 | 0.060 |
Why?
| Molecular Chaperones | 1 | 2003 | 64 | 0.060 |
Why?
| Alkaline Phosphatase | 1 | 2003 | 99 | 0.060 |
Why?
| Lipid Peroxidation | 1 | 2003 | 132 | 0.050 |
Why?
| Receptors, Vasoactive Intestinal Polypeptide, Type I | 1 | 2002 | 1 | 0.050 |
Why?
| Receptors, Vasoactive Intestinal Peptide | 1 | 2002 | 3 | 0.050 |
Why?
| Metabolome | 1 | 2023 | 109 | 0.050 |
Why?
| Superoxide Dismutase | 1 | 2003 | 125 | 0.050 |
Why?
| Glycoproteins | 1 | 2003 | 132 | 0.050 |
Why?
| Radioimmunoassay | 1 | 2002 | 41 | 0.050 |
Why?
| Metabolomics | 1 | 2023 | 149 | 0.050 |
Why?
| Peer Review | 1 | 2002 | 9 | 0.050 |
Why?
| Endocrine System | 1 | 2002 | 12 | 0.050 |
Why?
| Sp3 Transcription Factor | 1 | 2022 | 4 | 0.050 |
Why?
| Early Growth Response Protein 1 | 1 | 2002 | 39 | 0.050 |
Why?
| Neoplasm Invasiveness | 2 | 2014 | 295 | 0.050 |
Why?
| RNA Polymerase II | 1 | 2022 | 17 | 0.050 |
Why?
| Sp1 Transcription Factor | 1 | 2022 | 18 | 0.050 |
Why?
| Adenosine Triphosphatases | 1 | 2002 | 90 | 0.050 |
Why?
| STAT3 Transcription Factor | 1 | 2002 | 87 | 0.050 |
Why?
| Plant Proteins | 1 | 2002 | 72 | 0.050 |
Why?
| Membrane Glycoproteins | 1 | 2003 | 269 | 0.050 |
Why?
| Amino Acids | 1 | 2023 | 369 | 0.050 |
Why?
| Trans-Activators | 1 | 2002 | 147 | 0.050 |
Why?
| Mitochondria | 1 | 2005 | 489 | 0.050 |
Why?
| Mutation | 1 | 2007 | 1501 | 0.050 |
Why?
| Reactive Oxygen Species | 1 | 2003 | 491 | 0.050 |
Why?
| Alcohol Oxidoreductases | 1 | 2020 | 14 | 0.050 |
Why?
| Lymphangioleiomyomatosis | 1 | 2020 | 5 | 0.050 |
Why?
| Thyroid Gland | 1 | 2020 | 93 | 0.050 |
Why?
| Gene Expression Regulation, Developmental | 1 | 2020 | 151 | 0.040 |
Why?
| Hep G2 Cells | 1 | 2019 | 46 | 0.040 |
Why?
| Acetylcysteine | 1 | 2019 | 118 | 0.040 |
Why?
| Rats, Wistar | 1 | 2019 | 237 | 0.040 |
Why?
| Cross-Sectional Studies | 1 | 2023 | 1693 | 0.040 |
Why?
| Transcription Factors | 1 | 2002 | 622 | 0.040 |
Why?
| Fibrosis | 1 | 2019 | 208 | 0.040 |
Why?
| Apgar Score | 1 | 2017 | 35 | 0.040 |
Why?
| United States Environmental Protection Agency | 2 | 2007 | 9 | 0.040 |
Why?
| Diet, Atherogenic | 1 | 2017 | 9 | 0.040 |
Why?
| Biopsy | 1 | 2020 | 692 | 0.040 |
Why?
| China | 1 | 2017 | 104 | 0.040 |
Why?
| Injections, Intraperitoneal | 1 | 2017 | 59 | 0.040 |
Why?
| Bronchoalveolar Lavage Fluid | 1 | 2017 | 35 | 0.040 |
Why?
| Heart | 1 | 2020 | 360 | 0.040 |
Why?
| Pilot Projects | 1 | 2020 | 808 | 0.040 |
Why?
| Birth Weight | 1 | 2017 | 126 | 0.040 |
Why?
| National Institutes of Health (U.S.) | 2 | 2007 | 49 | 0.040 |
Why?
| Lung | 1 | 2020 | 507 | 0.040 |
Why?
| Mice, Knockout | 1 | 2019 | 926 | 0.040 |
Why?
| Sex Factors | 1 | 2019 | 767 | 0.030 |
Why?
| Time Factors | 2 | 2014 | 3213 | 0.030 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 206 | 0.030 |
Why?
| Hormone Replacement Therapy | 1 | 2015 | 27 | 0.030 |
Why?
| Acetaminophen | 1 | 2019 | 349 | 0.030 |
Why?
| Drug Implants | 1 | 2015 | 35 | 0.030 |
Why?
| Neoplasm Grading | 1 | 2015 | 131 | 0.030 |
Why?
| Sequence Analysis, DNA | 1 | 2016 | 273 | 0.030 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 153 | 0.030 |
Why?
| Models, Theoretical | 1 | 2016 | 184 | 0.030 |
Why?
| Sp Transcription Factors | 1 | 2014 | 6 | 0.030 |
Why?
| Organ Size | 1 | 2015 | 237 | 0.030 |
Why?
| Pentacyclic Triterpenes | 1 | 2014 | 8 | 0.030 |
Why?
| Lymphocyte Activation | 1 | 2015 | 197 | 0.030 |
Why?
| Triterpenes | 1 | 2014 | 13 | 0.030 |
Why?
| Neoplasm Transplantation | 1 | 2014 | 94 | 0.030 |
Why?
| Transplantation, Heterologous | 1 | 2014 | 77 | 0.030 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2015 | 76 | 0.030 |
Why?
| HMGA Proteins | 1 | 2014 | 2 | 0.030 |
Why?
| Immunity, Innate | 1 | 2015 | 114 | 0.030 |
Why?
| Caspase 7 | 1 | 2013 | 11 | 0.030 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2014 | 87 | 0.030 |
Why?
| Genome | 1 | 2014 | 74 | 0.030 |
Why?
| 5' Untranslated Regions | 1 | 2013 | 33 | 0.030 |
Why?
| Open Reading Frames | 1 | 2013 | 55 | 0.030 |
Why?
| Transcription Factor AP-2 | 1 | 2012 | 3 | 0.030 |
Why?
| Laser Capture Microdissection | 1 | 2012 | 7 | 0.030 |
Why?
| Life Style | 1 | 2014 | 156 | 0.030 |
Why?
| T-Lymphocytes | 1 | 2015 | 373 | 0.030 |
Why?
| DNA, Complementary | 1 | 2012 | 145 | 0.030 |
Why?
| Tissue Distribution | 1 | 2012 | 178 | 0.030 |
Why?
| Serum Response Factor | 1 | 2012 | 41 | 0.030 |
Why?
| Doxorubicin | 1 | 2013 | 259 | 0.030 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 101 | 0.030 |
Why?
| Neoplasm Recurrence, Local | 1 | 2016 | 644 | 0.030 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 99 | 0.030 |
Why?
| MAP Kinase Signaling System | 1 | 2012 | 133 | 0.030 |
Why?
| Antibodies | 1 | 2012 | 178 | 0.020 |
Why?
| Cisplatin | 1 | 2013 | 352 | 0.020 |
Why?
| Genotype | 1 | 2012 | 599 | 0.020 |
Why?
| Injections, Subcutaneous | 1 | 2010 | 58 | 0.020 |
Why?
| Cell Cycle | 1 | 2012 | 275 | 0.020 |
Why?
| Dihydrotestosterone | 1 | 2007 | 14 | 0.020 |
Why?
| Animals, Wild | 1 | 2007 | 11 | 0.020 |
Why?
| North Carolina | 1 | 2007 | 52 | 0.020 |
Why?
| Models, Animal | 1 | 2007 | 255 | 0.020 |
Why?
| Down-Regulation | 1 | 2007 | 388 | 0.020 |
Why?
| Public Health | 1 | 2002 | 206 | 0.010 |
Why?
|
|
Ho's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|